AU2013318146B2 - Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium - Google Patents

Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium Download PDF

Info

Publication number
AU2013318146B2
AU2013318146B2 AU2013318146A AU2013318146A AU2013318146B2 AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2 AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 A AU2013318146 A AU 2013318146A AU 2013318146 B2 AU2013318146 B2 AU 2013318146B2
Authority
AU
Australia
Prior art keywords
trospium
bladder
medicament
urine
treatment period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013318146A
Other languages
English (en)
Other versions
AU2013318146A1 (en
Inventor
Dennis GIESING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taris Biomedical LLC
Original Assignee
Taris Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical LLC filed Critical Taris Biomedical LLC
Publication of AU2013318146A1 publication Critical patent/AU2013318146A1/en
Application granted granted Critical
Publication of AU2013318146B2 publication Critical patent/AU2013318146B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
AU2013318146A 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium Ceased AU2013318146B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261702576P 2012-09-18 2012-09-18
US61/702,576 2012-09-18
PCT/US2013/060479 WO2014047221A1 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Publications (2)

Publication Number Publication Date
AU2013318146A1 AU2013318146A1 (en) 2015-03-19
AU2013318146B2 true AU2013318146B2 (en) 2018-05-10

Family

ID=49301639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013318146A Ceased AU2013318146B2 (en) 2012-09-18 2013-09-18 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium

Country Status (13)

Country Link
US (2) US10500200B2 (enExample)
EP (1) EP2897616A1 (enExample)
JP (2) JP6600256B2 (enExample)
KR (1) KR102141433B1 (enExample)
CN (2) CN104684556A (enExample)
AU (1) AU2013318146B2 (enExample)
BR (1) BR112015005351A2 (enExample)
CA (1) CA2883855C (enExample)
IL (1) IL237498B (enExample)
MX (2) MX379066B (enExample)
RU (1) RU2670749C9 (enExample)
SG (1) SG11201502104YA (enExample)
WO (1) WO2014047221A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
WO2014036556A2 (en) 2012-08-31 2014-03-06 Taris Biomedical, Inc. Drug delivery systems and methods for treatment of prostate
PL2890384T3 (pl) 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
EP2897616A1 (en) * 2012-09-18 2015-07-29 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium
PT3113782T (pt) 2014-03-06 2023-01-05 Taris Biomedical Llc Sistemas e métodos de administração de fármaco para tratamento do cancro da bexiga com gemcitabina
EP3183026B1 (en) * 2014-08-19 2019-10-30 The Regents of The University of California Implants for localized drug delivery and methods of use thereof
GB201506526D0 (en) 2015-04-17 2015-06-03 Uropharma Ltd And Synesis Llc Medicinal composition
CN106706832A (zh) * 2015-08-06 2017-05-24 舒泰神（北京）生物制药股份有限公司 一种测定曲司氯铵含量的方法
CN110418658A (zh) * 2017-02-01 2019-11-05 塔里斯生物医药公司 体内药物递送装置和药物递送的方法
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019315957A1 (en) * 2018-08-01 2021-02-18 Taris Biomedical Llc Methods of treating overactive bladder using trospium
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20220211615A1 (en) * 2019-04-30 2022-07-07 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
EP4100075A4 (en) 2020-03-20 2024-01-31 The Regents of University of California IMPLANTABLE DRUG RELEASE DEVICES FOR LOCALIZED DRUG RELEASE
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
KR102596697B1 (ko) 2021-05-20 2023-11-01 김정우 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998430A (en) * 1996-11-27 1999-12-07 Dr. R. Pfleger Chemische Fabrik Gmbh Use of trospium chloride and 2-component system for the same
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US20120203203A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled dissolution and diffusion of low solubility drug

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20060058777A1 (en) * 2002-12-11 2006-03-16 Pia Norup Nielsen Urinary catheter device with a pharmaceutically active composition
AU2004206846B2 (en) 2003-01-16 2009-05-28 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
DE602004020337D1 (de) 2004-08-11 2009-05-14 Boehringer Ingelheim Pharma Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
EP1933810B1 (en) 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EA201070703A1 (ru) 2007-12-11 2010-12-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарства и способы лечения мочевого пузыря и других полостей тела или трубчатых органов
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CA2765630C (en) 2009-06-26 2016-07-05 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
AU2010339821B2 (en) 2009-12-17 2015-02-19 Taris Biomedical Llc Implantable device with intravesical tolerability and methods of treatment
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2012048104A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Implantable drug delivery device with bladden retention feature
WO2012048114A1 (en) * 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2897616A1 (en) * 2012-09-18 2015-07-29 TARIS Biomedical LLC Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium
PL2968880T3 (pl) 2013-03-15 2025-06-23 Taris Biomedical Llc Urządzenia do dostarczania leku ze składnikiem przepuszczalnym dla leku

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998430A (en) * 1996-11-27 1999-12-07 Dr. R. Pfleger Chemische Fabrik Gmbh Use of trospium chloride and 2-component system for the same
WO2006101954A2 (en) * 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US20120203203A1 (en) * 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled dissolution and diffusion of low solubility drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAELI W et al:, ANNUAL TECHNICAL CONFERENCE - ANTEC 2009, , SOCIETY OF PLASTICS ENGINEERS USA, 2009, Vol. 5, pages 2951-2956, *
VON WALTER M et al: " TROSPIUM CHLORIDE RELEASED FROM INTRAVESICALLY APPLIED PLGA-BASED CARRIERS DECREASES BLADDER CONTRACTILITY IN AN ISOLATED WHOLE PIG BLADDER MODEL", EUROPEAN UROLOGY SUPPLEMENTS, 2009, 230, Vol. 8, no. 4, page 178 *

Also Published As

Publication number Publication date
CA2883855A1 (en) 2014-03-27
RU2670749C9 (ru) 2018-12-13
MX2015003110A (es) 2015-06-05
US11850244B2 (en) 2023-12-26
MX2020002465A (es) 2020-07-13
WO2014047221A9 (en) 2015-05-21
IL237498A0 (en) 2015-04-30
CN104684556A (zh) 2015-06-03
WO2014047221A1 (en) 2014-03-27
BR112015005351A2 (pt) 2017-07-04
KR20150058271A (ko) 2015-05-28
JP6600256B2 (ja) 2019-10-30
US20150182516A1 (en) 2015-07-02
JP2018080208A (ja) 2018-05-24
MX379066B (es) 2025-03-04
RU2670749C2 (ru) 2018-10-25
US20200108057A1 (en) 2020-04-09
AU2013318146A1 (en) 2015-03-19
US10500200B2 (en) 2019-12-10
JP2015529688A (ja) 2015-10-08
RU2015112196A (ru) 2016-11-10
SG11201502104YA (en) 2015-05-28
CA2883855C (en) 2020-09-15
CN111450093A (zh) 2020-07-28
EP2897616A1 (en) 2015-07-29
IL237498B (en) 2018-01-31
KR102141433B1 (ko) 2020-08-05

Similar Documents

Publication Publication Date Title
US11850244B2 (en) Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium
KR102157548B1 (ko) 방광암의 치료를 위한 옥살리플라틴을 포함하는 약물 전달 시스템과 방법
KR102383496B1 (ko) 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
JP2015529688A5 (enExample)
HK40026424A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
JP2016503406A5 (enExample)
HK40042011A (en) Drug delivery systems and methods for treatment of prostate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired